Journal
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
Volume 47, Issue 3, Pages 463-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ecl.2018.04.008
Keywords
Neuroendocrine neoplasm; Neuroendocrine tumor; Neuroendocrine carcinoma; Ki67; World Health Organization; American Joint Cancer Committee
Categories
Funding
- Novartis Pharma
- Ipsen Pharma
- University Cattolica [D.1/2014-R412500215, D.1 2015-R412500333]
- Associazione Italiana Ricerca sul Cancro - AIRC [IG 2013 14696]
Ask authors/readers for more resources
Based on the 2010 version, the 2017 World Health Organization (WHO 2017) classification is for pancreatic neuroendocrine neoplasms (PanNEN). The WHO 2017 classification introduces the novel well-differentiated neuroendocrine tumor of high grade (NET G3). A sharp distinction between NET and poorly differentiated neuroendocrine carcinoma is emphasized to highlight substantial biological differences. Further changes comprise the definition of mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN), to accommodate all grades of both neoplasm components, and the abolition of preneoplastic lesions given their rarity in the pancreas. The 2017 American Joint Cancer Committee classification (AJCC 2017) adopts such a classification for all digestive sites.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available